This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
The collaboration aims to help physicians improve detection and care of potentially treatable causes of cognitive decline SECAUCUS, N.J. and RALEIGH, N.C., May 4, 2023 /PRNewswire/ -- Quest...
First quarter revenues of $2.33 billion, down 10.7% from 2022 First quarter reported diluted earnings per share ("EPS") of $1.78, down 39.0% from 2022; and adjusted diluted EPS of $2.04, down...
Goal to improve patient outcomes through early, accurate detection of residual or recurring cancer Haystack's highly sensitive minimal-residual disease cancer-detection technology to be combined...
Quest Diagnostics (NYSE:DGX), the nation's leading provider of diagnostic information services, and NewYork-Presbyterian, one of the nation's largest and most comprehensive academic medical...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2023 financial results on Thursday, April...